Kling Biotherapeutics – Amsterdam Academic Ventures

Our portfolio

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

Industry: Infectious Disease, Oncology, Therapeutics

Want to get in contact about Kling Biotherapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Developing RNA-based therapies for rare genetic heart diseases.

Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.

Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.

Developing gene therapy solutions for heart rhythm disorders.

Developing RNA-based therapies for rare genetic heart diseases.

Digitizing stroke treatment development and planning with an in-silico stroke simulation platform.

Advancing nanotechnology with sustainable, solvent-free nanoparticle synthesis.

Developing gene therapy solutions for heart rhythm disorders.